African Americans, Kidney Disease, and Drug Development: A Regulatory Perspective  Carolina Panico, Aliza Thompson  American Journal of Kidney Diseases  Volume 72, Issue 5, Pages S33-S36 (November 2018) DOI: 10.1053/j.ajkd.2018.06.023 Copyright © 2018 Terms and Conditions

Figure 1 Demographics of efficacy trials by race for Veltassa (patiromer). Data source: US Food and Drug Administration.15 American Journal of Kidney Diseases 2018 72, S33-S36DOI: (10.1053/j.ajkd.2018.06.023) Copyright © 2018 Terms and Conditions

Figure 2 Demographics of efficacy trials by race for Entresto (sacubitril/valsartan). Data source: US Food and Drug Administration.15 ∗All other races combined. American Journal of Kidney Diseases 2018 72, S33-S36DOI: (10.1053/j.ajkd.2018.06.023) Copyright © 2018 Terms and Conditions